Foundayo (orforglipron) received a UK marketing authorisation from the MHRA on 10 August 2026, making it the first GLP-1 tablet of its kind to be approved in Europe. However, a licence permits a medicine to be prescribed — it does not mean any particular pharmacy stocks it. We do not supply orforglipron yet, and we intend to offer it once we are able to obtain it.
The short answer: approved, but not the same as "available"
There is an important distinction that trips people up when a new medicine makes headlines. A marketing authorisation (also called a licence) is a regulatory sign-off that a medicine can legally be prescribed and sold in the UK. It says nothing about whether a given clinic or pharmacy has chosen to dispense it.
So while Foundayo now has that authorisation, whether you can actually obtain it depends entirely on individual pharmacies and prescribers deciding to stock and prescribe it. Availability, pricing, and NHS access are separate questions that unfold over months, not overnight.
To be clear about our own position: we do not supply orforglipron yet. We intend to offer it once we are able to obtain it, and we will update this page when that happens. We cannot give a date, because that depends on wholesaler supply rather than on us.
What actually happened with Foundayo's approval
- 1 April 2026: the US Food and Drug Administration (FDA) approved orforglipron.
- 10 August 2026: the MHRA granted a UK marketing authorisation for weight management and type 2 diabetes — the first approval of this GLP-1 tablet in Europe.
That sequence is normal. Regulators in different territories assess the same clinical data on their own timelines, so a US approval often precedes a UK one by several months.
What is orforglipron?
Orforglipron is a small-molecule GLP-1 receptor agonist. Like other GLP-1 medicines, it works on the receptor for a natural gut hormone involved in appetite and fullness.
Its notable feature is that it survives digestion, so it can be taken as an ordinary once-daily pill — at any time of day, with or without food or water. That flexibility sets it apart from oral semaglutide, which must be taken on an empty stomach with strict timing rules.
The trial figure
In the Phase 3 ATTAIN-1 trial, participants on the 36mg dose lost on average 12.4% of their body weight over 72 weeks, alongside lifestyle counselling. Individual results vary; not everyone reaches this.
Is there a UK price yet?
No. There is no published UK price for orforglipron. Rather than estimate a figure, it is more honest to say plainly that no reliable UK cost exists at the time of writing.
Be cautious of any source quoting a confident UK price for it — there is no verified number to quote.
When will the NHS fund it?
NHS funding is a separate decision from the MHRA licence. In England, that route runs through NICE, which appraises whether a medicine is cost-effective for NHS use. No date for this has been confirmed, and there is no published NICE timetable for orforglipron.
In short: the MHRA has said the medicine can be prescribed; NICE has not yet said whether the NHS will pay for it. These are two different questions.
What can you access at The Weight Clinic right now?
Until we are able to offer Foundayo, there are several MHRA-licensed, in-stock weight-management medicines available after a clinical consultation. These may be worth exploring with a prescriber:
| Medicine | Form | From |
|---|---|---|
| Mounjaro (tirzepatide) | Weekly injection | £160/month |
| Wegovy injection (semaglutide) | Weekly injection | £115/month |
| Wegovy Tablet (oral semaglutide) | Once-daily tablet | £115/month |
If a daily tablet appeals to you, the Wegovy Tablet is a licensed oral option that is live and in stock. It is taken first thing on an empty stomach with a small sip of plain water, then you wait at least 30 minutes before eating, drinking anything else, or taking other medicines — taken with food it is far less effective.
You can browse everything on our treatments overview or the combined weight-loss injections page.
Who is eligible for weight-management medicines?
Eligibility is consistent across the licensed injectables and the tablet we supply. In general terms, you may be suitable if you are:
- Aged 18 or over; and
- Have a BMI of 30 or above (obesity); or
- Have a BMI of 27–30 with a weight-related condition such as type 2 diabetes, high blood pressure or sleep apnoea.
These medicines are not suitable for everyone. They are generally not appropriate if you are pregnant, planning pregnancy or breastfeeding; have type 1 diabetes; have a personal or family history of medullary thyroid carcinoma or MEN2; have a history of pancreatitis; have severe gastrointestinal disease; have an active eating disorder; have severe liver or kidney impairment; or are allergic to the active ingredient.
A treatment is prescribed only if it is clinically appropriate after a consultation with a GPhC-registered prescriber. You can begin the free online consultation to check whether a licensed option is right for you — a prescription is never guaranteed.
Side effects to be aware of
GLP-1 medicines share a common side-effect profile. Common effects (affecting more than 1 in 10 people) include nausea, diarrhoea, constipation, vomiting, decreased appetite and fatigue. Rare but serious risks include severe allergic reaction, acute pancreatitis, severe hypoglycaemia, severe gastrointestinal disease and worsening diabetic retinopathy.
If you experience a side effect from any medicine, you can report it through the MHRA Yellow Card scheme at https://yellowcard.mhra.gov.uk/.
The bottom line
Foundayo (orforglipron) is UK-authorised as of 10 August 2026, but authorisation is not the same as availability — and we do not supply it yet, though we intend to once we are able to obtain it. There is no confirmed UK price and no confirmed NHS funding date.
If you want to understand the licensed options that are available now, read more about Mounjaro, the Wegovy injection and the Wegovy Tablet, or visit the Foundayo reference page for factual background. You can also learn about how we work or read more on our blog.
This article is for information only and is not a substitute for personalised medical advice. Weight-loss medicines are prescription-only, are not suitable for everyone, and are prescribed only after a clinical consultation with a GPhC-registered prescriber. Individual results vary. Always speak to a UK-registered pharmacist or doctor before starting or changing any prescription medication.
